Savara (SVRA) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Savara Inc. is running a Phase 3 study called “An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).” The study tracks how well children with this rare lung disease respond to inhaled treatment, with a focus on breathing, activity, and safety over one year.
The only treatment in this trial is inhaled molgramostim, a drug delivered by nebulizer once a day. It is designed to help clear protein build-up in the lungs and improve how well children with aPAP can breathe and function day to day.
The trial is interventional and open-label, meaning all enrolled children get molgramostim and there is no placebo group. It uses a single-group design with no blinding, and the main goal is treatment, so results will show real-world use rather than a head-to-head comparison.
The study was first submitted on May 22, 2024, marking the formal launch of this pediatric program. The record was last updated on Feb. 17, 2026, showing that the plan and recruitment status are current while the trial is still in progress.
For investors, this update supports Savara’s push to build a franchise in rare lung diseases, adding a pediatric angle that could expand the long-term market if data are positive. Progress in aPAP also helps defend Savara’s position against larger respiratory players and could improve sentiment toward SVRA as investors look for de-risking milestones and potential label expansion.
The study is ongoing and recently updated, with more details available on the ClinicalTrials.gov portal under NCT06431776.
To learn more about SVRA’s potential, visit the Savara drug pipeline page.